NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Addex Therapeutics Ltd. ADXN
8 fiscal years on record · CHF · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
CHF 404,102
▼ 74.9% vs FY2023
EPS · FY24
CHF 0.07
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
—
Net margin · FY24
1746.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
CHF 404,102.00
Revenue, FY2024 · full 8-year series below
Revenue
Net income
1746 cents of every revenue dollar became profit this year.
Per share
CHF 0.07
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2024
ROE
Operating margin-681.8%
Net margin1746.0%
Return on assets92.1%
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−31.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−48.3%
−31.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.13B
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
CHF 10.7M
total assets, end of FY2024
Total assetsCHF 10.7M
CashCHF 3.3M
Current ratio4.42×
History
8 fiscal years
Every figure from documents filed with the SEC · CHF
Metric
2024
2023
2022
2021
2020
2019
2018
2017
Revenue CHF B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income CHF B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA CHF B
·
·
·
·
·
·
·
·
Income tax CHF B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Net income CHF B
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted CHF
0.07
−0.14
−0.46
−0.45
−0.48
−0.56
·
·
Dividend / sh CHF
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
Shares out B
0.13
0.13
0.08
0.04
0.03
0.03
0.03
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
20 of 20
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed